Drug Profile
Atropine dry-powder inhalation - MicroDose Therapeutx
Alternative Names: Atropine sulfate dry-powder inhalation - MicroDose Therapeutx; MDT-010Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator MicroDose Therapeutx
- Class Alkaloids; Antidotes; Cardiovascular therapies; Eye disorder therapies; Small molecules; Tropanes
- Mechanism of Action Cholinergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Poisoning
Most Recent Events
- 24 Mar 2016 No recent reports on development identified - Phase-I for Poisoning (In volunteers) in USA (Inhalation)
- 08 Jul 2013 MicroDose Therapeutx has been acquired by Teva Pharmaceutical Industries
- 24 Sep 2009 Phase-I clinical trials in Poisoning in USA (Inhalation)